Palliative chemotherapy for malignant ascites secondary to ovarian cancer (Q37987902)

26 August 2017

Palliative chemotherapy for malignant ascites secondary to ovarian cancer (English)

1 reference

26 August 2017

1 reference

1 reference

Yuliya Malayev

1

1 reference

PubMed ID

22363037

26 August 2017

Richard Levene

series ordinal

2

1 reference

PubMed ID

22363037

26 August 2017

Faustino Gonzalez

series ordinal

3

1 reference

26 August 2017

23 February 2012

1 reference

American Journal of Hospice and Palliative Medicine

26 August 2017

1 reference

26 August 2017

29

1 reference

26 August 2017

7

1 reference

26 August 2017

515-521

1 reference

Recent progress in the diagnosis and treatment of ovarian cancer

26 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

A review of issues surrounding quality of life among women with ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Frequency of symptoms of ovarian cancer in women presenting to primary care clinics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Effect of Screening on Ovarian Cancer Mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Identifying patients unlikely to benefit from further chemotherapy: a descriptive study of outcome at each relapse in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

21 January 2018

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

The role of chemotherapy at the end of life: "when is enough, enough?".

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Intraperitoneal drug therapy: an advantage

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Palliation of malignant ascites

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Gynaecological malignancies from palliative care perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Expandable metal stents for the treatment of cancerous obstruction of the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Gynecologic oncology patients' satisfaction and symptom severity during palliative chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Attitudes to chemotherapy in patients with ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

End of life care for women with gynecologic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Futility: clinical decisions at the end-of-life in women with ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

The influence of personal expectations on cancer patients' reports of health-related quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Treatment preferences in recurrent ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Hospice enrollment for terminally ill patients with gynecologic malignancies: impact on outcomes and interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Resource implications of palliative chemotherapy for ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Resource utilization for ovarian cancer patients at the end of life: how much is too much?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Immunomodulatory effects of cyclophosphamide and implementations for vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Metronomic scheduling: the future of chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Feasibility study of oral cyclophosphamide salvage therapy for the treatment of heavily pretreated patients with recurrent epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Thalidomide-induced reversible interstitial pneumonitis in a patient with recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Antiangiogenic potential of camptothecin and topotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Topotecan in platinum- and paclitaxel-resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Tamoxifen inhibits cell proliferation via mitogen-activated protein kinase cascades in human ovarian cancer cell lines in a manner not dependent on the expression of estrogen receptor or the sensitivity to cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evalu

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Case records of the Massachusetts General Hospital. Case 11-2006. A 54-year-old woman with a mass in the pelvis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Intraperitoneal antineoplastic drug delivery: rationale and results

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Clinical predictors of bevacizumab-associated gastrointestinal perforation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909111434044

21 January 2018

Identifiers

DOI

10.1177/1049909111434044

1 reference

26 August 2017

1 reference

PubMed ID

22363037